Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Jennifer Vergara-Jimenez, Pierluigi TricociDepartment of Medicine-Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USAAbstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (P...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-03-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/safety-and-efficacy-of-abciximab-as-an-adjunct-to-percutaneous-coronar-a4025 |